# Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus

> **NCT03110445** · PHASE1 · WITHDRAWN · sponsor: **University Hospital, Basel, Switzerland**

## Conditions studied

- Breast Carcinoma

## Interventions

- **BIOLOGICAL:** rVV-740CTA

## Key facts

- **NCT ID:** NCT03110445
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** not sufficiently staff available to perform trial
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03110445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03110445, "Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03110445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*